Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 7/20 | 0.63 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | NEK7 | Q8TDX7 | 2/20 | 0.46 |
| ▸ | CACNA1H | O95180 | 8/20 | 0.44 |
| ▸ | WNT3A | P56704 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1256365 | 0.97 | KIT (0.62) | KITFLT3NEK7CACNA1HWNT3A | |
| SCHEMBL1255321 | 0.90 | KIT (0.62) | KITFLT3NEK7CACNA1H | |
| SCHEMBL1255022 | 0.90 | KIT (0.64) | KITFLT3NEK7CACNA1HWNT3A | |
| SCHEMBL1256936 | 0.88 | KIT (0.51) | KITCACNA1HWNT3A | |
| SCHEMBL1256991 | 0.88 | KIT (0.63) | KITFLT3NEK7CACNA1HWNT3A | |
| SCHEMBL1255264 | 0.88 | KIT (0.62) | KITFLT3NEK7CACNA1HWNT3A | |
| SCHEMBL1257149 | 0.87 | KIT (0.61) | KITFLT3NEK7CACNA1HWNT3A | |
| SCHEMBL1257227 | 0.85 | KIT (0.49) | KITCACNA1HWNT3A | |
| SCHEMBL1256046 | 0.85 | KIT (0.56) | KITFLT3NEK7CACNA1H | |
| SCHEMBL1255143 | 0.84 | KIT (0.59) | KITFLT3NEK7CACNA1HWNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-02-07 | — | — | US | claimed |
| EP-2467137-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2012-06-27 | — | — | EP | claimed |
| WO-2011022473-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2011-02-24 | — | — | WO | claimed |
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-02-07 | — | — | US | disclosed |
| EP-2467137-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011022473-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | FLT3, CSF3R, CSF1R | KIT 4/4885FLT3 1/4885NEK7 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.